Description
Abstract
This paper reviews the current evidence on disease burdens
and likely future growth among patients in the ‘moderate’
group. New drug therapy can provide leverage for low cost
improvements in programmes.
£25.00
Author(s): N Bosanquet
This paper reviews the current evidence on disease burdens
and likely future growth among patients in the ‘moderate’
group. New drug therapy can provide leverage for low cost
improvements in programmes.
Author(s): S M Benbow
Author(s): J Hepple
Author(s): Sube Banerjee
Author(s): D Wilkinson
Author(s): C Bowman & J Dovey
Author(s): Gillian Stewart & Martin Zeidler
